The newly granted patents, issued by the United States Patent and Trademark Office and the Japan Patent Office, protect the distal design that enables the device to penetrate the vessel wall and advance towards the intended site. The patents are valid for 20 years, in line with international standards, and mirror the claims of the European patent.
SmartCella secures key patents in the US and Japan
Swedish drug-delivery company SmartCella has secured the main patent for its Extroducer device in the US and Japan, completing global protection following the European approval granted in 2024.
Advertisement
BREAKING